Five years outcome of Antivegef Injection for management of Diabetic Macular Edema
Abstract
Background: Intravitreal injections (IVI) of anti-vascular endothelial growth factor (anti-VEGF) are used to treat diabetic macular edema (DME).
Material & Method: Retrospective electronic data review for four years after starting treatment and prospective recording for an additional 1 year were conducted to assess the five years visual outcome of anti-VEGEF injections in the treatment of DME. Main outcome was visual acuity 5 years after starting the treatment.
Results: One hundred eyes were evaluated, the median of vision all over the five years had improved compared to the Baseline; this difference was statistically significant all over the five years in total (P 0.001), but by comparing each year to the baseline vision, the statistically significant difference was noted for the first four years only, while the 5th year vision difference from Baseline was not statically significance P0 (0.484).
Conclusion: Anti-VEGFs produce a significant improvement in best-corrected visual acuity (BCVA) in patients with DME but this improvement is lost after 5 years of follow-up.
